Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-09-22FDA Approved: LATANOPROST — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for latanoprost from Rising Pharma Holdings, Inc., granting a new generic latanoprost product un…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5% [Phase 3]
Phase 3 randomized study comparing two travoprost intraocular implant models to timolol maleate ophthalmic solution 0.5%; results have been …
-
CLINICAL_TRIALS trial_result · 2023-08-30Clinical Trial Update: A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study [Phase 3]
A Phase III study comparing DE-117 ophthalmic solution to timolol for glaucoma or ocular hypertension completed with posted results.
-
CLINICAL_TRIALS trial_result · 2023-08-30Clinical Trial Update: DE-117 Spectrum 5 Study [Phase 3]
Phase 3 trial update for DE-117 Spectrum 5 in primary open-angle glaucoma and ocular hypertension has completed with results posted.
-
FDA approval · 2023-08-25FDA Approved: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved the original application for a fixed-dose combination eye drop containing brimonidine tartrate and timolol maleate, manufacture…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-22Clinical Trial Update: A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months [Phase 2]
A Phase 2 trial evaluating the safety and ocular hypotensive effect of AR-12286 in patients with elevated intraocular pressure, completed.
-
FDA approval · 2023-08-14FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for dorzolamide hydrochloride and timolol maleate ophthalmic solution from Bausch & Lomb Incorporate…
-
CLINICAL_TRIALS trial_result · 2023-08-09Clinical Trial Update: A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study [Phase 3]
Phase III study comparing DE-117 ophthalmic solution to timolol for glaucoma or ocular hypertension; trial completed with results posted in …
-
FDA approval · 2023-08-01FDA Approved: BRIMONIDINE TARTRATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved brimonidine tartrate for an original application (ANDA) from Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-07-28FDA Approved: BRINZOLAMIDE — Original Application (Padagis US LLC)
FDA approved the original ANDA for brinzolamide from Padagis US LLC, authorizing a generic brinzolamide product.
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients. [Phase 3]
A Phase 3 trial comparing T4030 Eye Drops with Ganfort in patients with ocular hypertension or glaucoma has completed, assessing efficacy an…
-
CLINICAL_TRIALS trial_result · 2023-07-12Clinical Trial Update: Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma [Phase 2]
Phase 2 trial update on safety and efficacy of ophthalmic phentolamine mesylate for open-angle glaucoma and ocular hypertension.
-
FDA approval · 2023-06-28FDA Approved: BRINZOLAMIDE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for brinzolamide from Sandoz Inc, signaling a regulatory update to the product.
-
FDA approval · 2023-06-22FDA Approved: LEVOBUNOLOL HYDROCHLORIDE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for levobunolol hydrochloride (generic beta-blocker) from Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert [Phase 3]
Phase 3 study completed evaluating the long-term safety of the sustained-release travoprost intracanalicular insert (OTX-TP).
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3b study evaluating 24-hour intraocular pressure lowering effect of Bimatoprost SR in open-angle glaucoma or ocular hypertension has c…
-
FDA approval · 2023-06-02FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE PRESERVATIVE FREE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application to authorize a preservative-free version of dorzolamide hydrochloride and timolol maleate eye drops …
-
FDA approval · 2023-05-26FDA Approved: TIMOLOL MALEATE — Original Application (Micro Labs Limited)
The FDA approved Micro Labs Limited's original ANDA for Timolol Maleate Ophthalmic, a generic eye drop used to lower intraocular pressure in…
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma [Phase 2]
A Phase 2 trial investigating AKB-9778 ophthalmic solution as an adjunct to latanoprost in ocular hypertension or primary open-angle glaucom…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial update for Levobetaxolol Hydrochloride Eye Drops in primary open-angle glaucoma and ocular hypertension has completed.
-
FDA approval · 2023-05-08FDA Approved: TIMOLOL MALEATE — Original Application (Armas Pharmaceuticals, Inc.)
FDA approved TIMOLOL MALEATE as an Original Application (ANDA) for Armas Pharmaceuticals, a generic ophthalmic solution indicated to reduce …
-
FDA approval · 2023-05-05FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)
FDA approves a supplemental application for Simbrinza (brinzolamide/brimonidine tartrate) from Alcon Laboratories, Inc.
-
FDA approval · 2023-05-01FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved Ingenus Pharmaceuticals' original application for a dorzolamide hydrochloride and timolol maleate combination eye drop to reduc…
-
FDA approval · 2023-04-26FDA Approved: LATANOPROST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for LATANOPROST from Sandoz Inc (AP), marking regulatory approval for this generic glaucoma therapy.
-
FDA approval · 2023-03-29FDA Approved: BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION, 0.15% — Original Application (Alembic Pharmaceuticals Limited)
FDA approves Brimonidine tartrate ophthalmic solution 0.15% from Alembic Pharmaceuticals as an Original Application (ANDA) for lowering intr…